Stock Research: Virbac

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Virbac

ENXTPA:VIRP FR0000031577
65
  • Value
    75
  • Growth
    13
  • Safety
    Safety
    77
  • Combined
    56
  • Sentiment
    57
  • 360° View
    360° View
    65
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Virbac SA is a veterinarian pharmaceutical company specializing in developing and producing vaccines and medicines. It operates in the pharmaceutical industry, offering pet and livestock medications, as well as food and identification chips for pets. Production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. In the last fiscal year, the company had a market cap of $3,328 million, profits of $971 million, and revenue of $1,447 million, with 5620 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 65 (better than 65% compared with alternatives), overall professional sentiment and financial characteristics for the stock Virbac are above average. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Virbac. The consolidated Value Rank has an attractive rank of 77, which means that the share price of Virbac is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 77% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 75. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 57. But the consolidated Growth Rank has a low rank of 13, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 87 of its competitors have better growth. ...read more

more
Index
CAC All
SBF 120
SDG 1
SDG 15
SDG 2
SDG 3
SDG 6
Sound Pay Europe
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
77 60 47 52
Growth
13 79 59 97
Safety
Safety
75 85 84 62
Sentiment
57 79 78 50
360° View
360° View
65 92 94 84
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
76 38 41 1
Opinions Change
9 62 94 50
Pro Holdings
n/a 80 61 100
Market Pulse
65 65 53 49
Sentiment
57 79 78 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
77 60 47 52
Growth
13 79 59 97
Safety Safety
75 85 84 62
Combined
56 81 80 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
67 54 33 32
Price vs. Earnings (P/E)
67 59 63 69
Price vs. Book (P/B)
57 45 43 43
Dividend Yield
35 41 43 49
Value
77 60 47 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
29 62 42 45
Profit Growth
49 67 37 83
Capital Growth
31 95 40 98
Stock Returns
23 35 96 100
Growth
13 79 59 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
60 78 76 63
Refinancing
59 50 61 44
Liquidity
78 68 79 48
Safety Safety
75 85 84 62

Similar Stocks

Discover high‑ranked alternatives to Virbac and broaden your portfolio horizons.

Rubis

ENXTPA:RUI
Country: France
Industry: Gas Utilities
Size: Medium
Full Stock Analysis

Synergie

ENXTPA:SDG
Country: France
Industry: HR- & Employment Services
Size: Medium
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.